New Antibiotic Beats Superbugs (MRSA) At Their Own Game

This looks to be very good news. Everywhere MRSA is taking it’s toll on hospitals and in the wild as well. The bug in the wild is ever more potent than what is normally contracted at a hospital. Hopefully this one will prove to be potent enough soon for release on the market. The testing on this has be unique and make a bit of a new case for antibiotic research. BD

Rockefeller University scientists tested the new drug, called Ceftobiprole, against some of the deadliest strains of multidrug-resistant Staphylococcus aureus (MRSA) bacteria, which are responsible for the great majority of staphylococcal infections worldwide, both in hospitals and in the community.The drug is effective because the chemists who developed Ceftobiprole managed to outwit the bacteria at their own game, Tomasz says. The broad-spectrum antibiotic was discovered by Basilea Pharmaceuticals, based in Basel, Switzerland, and is being developed in the U.S. and worldwide by Johnson & Johnson. The research was supported by Johnson & Johnson along with a grant from the U.S. Public Health Service.